Related Experiment Video
Updated: Aug 13, 2026
07:18
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
CD22 regulates Aβ clearance in microglia through INPP5D signaling
De-Zhi Zou1, Jun Li2, Qiu-Shuang Long3
1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in Cellular Neuroscience
|August 12, 2026
Summary
Impaired microglial amyloid-beta clearance drives Alzheimer's disease (AD). We found CD22 restrains this process, revealing a CD22-INPP5D pathway that limits amyloid-beta degradation, offering a potential therapeutic target for AD.
Area of Science:
- Neuroscience
- Immunology
- Molecular Biology
Background:
- Impaired microglial clearance of amyloid-beta (Aβ) is a key factor in Alzheimer's disease (AD) pathogenesis.
- The precise mechanisms controlling intracellular Aβ degradation within microglia are not fully understood.
Purpose of the Study:
- To investigate the role of CD22 in microglial Aβ processing.
- To identify molecular regulators of intracellular Aβ degradation in the context of AD.
Main Methods:
- Primary microglia cultures
- Transcriptomic profiling
- Analysis of hippocampal samples from AD patients and transgenic mouse models
Main Results:
- CD22 expression is elevated in AD brains and induced by Aβ in microglia.
- CD22 acts as an Aβ-inducible regulator that restrains microglial Aβ processing.
- A CD22-INPP5D signaling axis was identified, where CD22 suppresses INPP5D, promoting Aβ degradation. Aβ induces CD22, creating a feedback loop limiting its own clearance.
Conclusions:
- The CD22-INPP5D axis is a novel regulatory mechanism for intracellular Aβ degradation.
- This pathway represents a potential therapeutic target for enhancing microglial Aβ clearance in Alzheimer's disease.
